G1 Therapeutics Inc
NASDAQ:GTHX

Watchlist Manager
G1 Therapeutics Inc Logo
G1 Therapeutics Inc
NASDAQ:GTHX
Watchlist
Price: 7.15 USD Market Closed
Market Cap: 377.2m USD

Operating Margin
G1 Therapeutics Inc

-65.1%
Current
-249%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-65.1%
=
Operating Profit
-37.9m
/
Revenue
58.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
G1 Therapeutics Inc
NASDAQ:GTHX
376.8m USD
-65%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
335.2B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.5B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
145B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
130.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.1B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

G1 Therapeutics Inc
Glance View

Market Cap
376.8m USD
Industry
Biotechnology

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

GTHX Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-65.1%
=
Operating Profit
-37.9m
/
Revenue
58.2m
What is the Operating Margin of G1 Therapeutics Inc?

Based on G1 Therapeutics Inc's most recent financial statements, the company has Operating Margin of -65.1%.

Back to Top